While the development and approval of biosimilars, especially monoclonal antibodies (mAbs), are moving at a snail's pace in developed countries, the copycat drugs are racing forward in Asia and Latin America.
While the development and approval of biosimilars, especially monoclonal antibodies (mAbs), are moving at a snail's pace in developed countries, the copycat drugs are racing forward in Asia and Latin America.
Superbugs are staging a global onslaught that will only get worse with time unless a modernized arsenal is developed to stop them. But an inventory of new weapons under development doesn't look like enough is being done to turn the tide anytime soon.
Congress is running out of patience with the SEC's continued delay in implementing part of the Jumpstart Our Business Startups (JOBS) Act that was supposed to be in place last year.
A determination letter slapping the lead university in a federally funded neonatal trial resulted in a government watchdog calling on the Department of Health and Human Services (HHS) to suspend enrollment in similar trials until it gets an independent review to ensure that parents will be adequately informed of potential risks to their babies.
Amazonian plants plucked from the ground. Baseball bats emerging from trees. Chocolate chip cookie ingredients separated from the dough. They were all part of the discussion Monday as the Supreme Court grappled with the science behind Myriad Genetics Inc.'s gene-based claims – and patent law itself.
Among the thousands of interesting people who will be attending the 2013 BIO International Convention in Chicago, which kicks off one week from today, are young standouts who are already making their mark in biotech.
Biotech Supreme Court watchers are looking at the what ifs ahead of Monday's arguments in a case that could overturn 30 years of established precedent, undoing isolated DNA claims and possibly threatening thousands of patents on proteins and other compounds that could be deemed "products of nature."
The $3.77 trillion budget proposal for fiscal 2014 that the White House unveiled Wednesday offers drugmakers a mixed bag of good news and bad news in terms of tax reforms and health care spending.